QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Near Add Your Location

Sorting 38 by

University of Chicago Medicine
Comprehensive Cancer Center
Chicago, IL
  • Accepting patients
Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
  • Accepting patients
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
University of Wisconsin - Carbone Cancer Center
University of Wisconsin Health
Madison, WI
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.